KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Liabilities (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Total Liabilities for 18 consecutive years, with $3.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities rose 26.58% year-over-year to $3.0 billion; the TTM value through Mar 2026 reached $3.0 billion, up 26.58%, while the annual FY2025 figure was $3.0 billion, 25.65% up from the prior year.
  • Total Liabilities hit $3.0 billion in Q1 2026 for Ionis Pharmaceuticals, down from $3.0 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $3.0 billion in Q4 2025 and bottomed at $1.8 billion in Q1 2022.
  • Average Total Liabilities over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2024.
  • Year-over-year, Total Liabilities surged 43.28% in 2023 and then decreased 7.63% in 2024.
  • Ionis Pharmaceuticals' Total Liabilities stood at $2.0 billion in 2022, then soared by 32.76% to $2.6 billion in 2023, then decreased by 7.22% to $2.4 billion in 2024, then rose by 25.65% to $3.0 billion in 2025, then fell by 2.51% to $3.0 billion in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $3.0 billion, $3.0 billion, and $2.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.